Using advanced sequencing technology, investigators from Brigham and Women’s Hospital, along with collaborators from the Broad Institute and MIT find dramatically altered cells in nasal polyps and other clues about inflammatory diseases. The team’s findings are published online in Nature.
‘Nasal polyps offer insights into allergic diseases (9:30 am)’
Barrett and colleagues obtained samples from 12 patients with nasal polyps or other sinus conditions, for a total collection of 18,036 cells. They compared these to nasal scrapings from healthy individuals. Barrett and her team member Dan Dwyer, PhD, partnered with Alex K. Shalek, PhD, of the Broad Institute, Ragon and MIT, and his postdoctoral fellow Jose Ordovas-Montanes, PhD, to use massively-parallel, single-cell RNA sequencing – a technique that allows investigators to determine genes turned on in each cell recovered. Rather than focusing on just one kind of suspected cell, they used this approach to look at every cell type found in harvested samples.
What they found surprised them. One of the most striking findings the researchers reported was that epithelial progenitor cells, stem-like cells which give rise to the cells that line the airways, had been completely remodeled in the polyp samples. And they had been permanently altered. In fact, even when removed from the tissue and grown in the lab, the resulting cells showed marked genetic differences.
“We found that stem-like epithelial cells expressed an aberrant program,” said Barrett. “To a dramatic extent, inflammation had changed the basic tissue architecture at the genetic level.”
The Nature publication offers a global, cellular map of inflamed tissue for what is known as type 2 inflammation – a severe form of inflammation that involves immune cells that have gone rogue, triggering a cascade of immune action. The map points to many pathways that have been altered, and Barrett and colleagues are working through these to identify which ones may be driving inflammation and which ones may be resulting from the inflammatory process. The research team also tested a monoclonal antibody that helped restore normal genetic activity – suggesting that it may be possible to develop therapies in the future to restore a normal balance to cells that have been altered through inflammation.
The team also hopes to use the new information to develop a genetic signature that would allow clinicians to take a swab of nasal mucosa to test for lung conditions. Using the new map to chart the key characteristics of type 2 inflammation could yield the tools needed to predict disease states and, potentially, direct targeted therapy.